1,317
Views
1
CrossRef citations to date
0
Altmetric
Research Paper

Adiponectin – stratification biomarker in diastolic cardiac dysfunction

, , ORCID Icon, , , , , , & ORCID Icon show all
Article: 2171030 | Received 04 Sep 2022, Accepted 17 Jan 2023, Published online: 24 Jan 2023

References

  • Diaconu A, Coculescu B-I, Manole G, Vultur H, Coculescu EC, Stocheci CM, Tudorache I-S, Dincă A-L, Dincă VG. Lipoprotein-associated phospholipase A2 (Lp-PLA2) – possible diagnostic and risk biomarker in chronic ischaemic heart disease. J Enzyme Inhib Med Chem. 2021;36(1):68–73.
  • Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356.
  • Snyder ML, Love S-A, Sorlie PD, Rosamond WD, Antini C, Metcalf PA, Hardy S, Suchindran CM, Shahar E, Heiss G, et al. Redistribution of heart failure as the cause of death: the atherosclerosis risk in communities study. Popul Health Metr. 2014;12(1):10.
  • Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? Cardiol Clin. 2007;25(4):487–495.
  • Khoramipour K, Chamari K, Hekmatikar AA, Ziyaiyan A, Taherkhani S, Elguindy NM, Bragazzi NL. Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition. Nutrients. 2021;13(4):1180.
  • Choi HM, Doss HM, Kim KS. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci. 2020;21(4):1219.
  • Liu Y, Vu V, Sweeney G. Examining the potential of developing and implementing use of adiponectin-targeted therapeutics for metabolic and cardiovascular diseases. Front Endocrinol. 2019;10:842.
  • Roy B, Palaniyandi SS. Tissue-specific role and associated downstream signaling pathways of adiponectin. Cell Biosci. 2021;11(1):77.
  • Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018;8(3):1031–1063.
  • Esfahani M, Shabab N, Saidijam M. AdipoRon may be benefit for atherosclerosis prevention. Iran J Basic Med Sci. 2017;20(2):107–109.
  • Lee B, Shao J. Adiponectin and energy homeostasis. Rev Endocr Metab Disord. 2014;15(2):149–156.
  • Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207–258.
  • Zhang P, Wang Y, Fan Y, Tang Z, Wang N. Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29(1):67–74.
  • Senoner T, Dichtl W. Oxidative stress in cardiovascular diseases: still a therapeutic target? Nutrients. 2019;11(9):2090.
  • D’Oria R, Schipani R, Leonardini A, et al. The role of oxidative stress in cardiac disease: from physiological response to injury factor. Oxid Med Cell Longev. 2020;2020:5732956.
  • Agrimi J, Spalletti C, Baroni C, Keceli G, Zhu G, Caragnano A, Matteucci M, Chelko S, Ramirez-Correa GA, Bedja D, et al. Obese mice exposed to psychosocial stress display cardiac and hippocampal dysfunction associated with local brain-derived neurotrophic factor depletion. EBioMedicine. 2019;47:384–401.
  • Kibel A, Lukinac AM, Dambic V, Juric I, Selthofer-Relatic K. Oxidative stress in ischemic heart disease. Oxid Med Cell Longev. 2020;2020:1–30.
  • Zhu C, Hu DL, Liu YQ, Zhang QJ, Chen FK, Kong XQ, Cao KJ, Zhang JS, Qian LM. Fabp3 inhibits proliferation and promotes apoptosis of embryonic myocardial cells. Cell Biochem Biophys. 2011;60(3):259–266.
  • Hui X, Lam KSL, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012;165(3):574–590.
  • López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014;18(1):37–45.
  • Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016;8(2):93–100.
  • Lau WB, Ohashi K, Wang Y, Ogawa H, Murohara T, Ma X-L, Ouchi N. Role of adipokines in cardiovascular disease. Circ J. 2017;81(7):920–928.
  • Parker-Duffen JL, Walsh K. Cardiometabolic effects of adiponectin. Best Pract Res Clin Endocrinol Metab. 2014;28(1):81–91.
  • Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, et al. Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85–89.
  • Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis C, Tousoulis D. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9(7):781.
  • Coculescu BI, Manole G, Coculescu EC, et al. Autophagy as a neuronal survival mechanism in ischemic stroke. Rom J Leg Med. 2018;26(4):333–339.
  • Lin P, Ji H-H, Li Y-J, Guo S-D. Macrophage plasticity and atherosclerosis therapy. Front Mol Biosci. 2021;8:679797.
  • Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, Fallah P, Bazi Z. Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag. 2015;11:55–70.
  • Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380(1–2):24–30.
  • Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.
  • da Silva Rosa SC, Liu M, Sweeney G. Adiponectin synthesis, secretion and extravasation from circulation to interstitial space. Physiology. 2021;36(3):134–149.
  • Aljafary MA, Al-Suhaimi EA. Adiponectin system (Rescue Hormone): the missing link between metabolic and cardiovascular diseases. Pharmaceutics. 2022;14(7):1430.
  • (a) Cohen KE, Katunaric B, SenthilKumar G, McIntosh JJ, Freed JK. Vascular endothelial adiponectin signaling across the life span. Am J Physiol Heart Circ Physiol. 2022;322(1):H57–H65. (b) Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10(3):269–279.
  • Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A, Daniele A. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014;2014:658913.
  • Caselli C, D’Amico A, Cabiati M, Prescimone T, Del Ry S, Giannessi D. Back to the heart: the protective role of adiponectin. Pharmacol Res. 2014;82:9–20.
  • Yoo HJ, Choi KM. Adipokines as a novel link between obesity and atherosclerosis. World J Diabetes. 2014;5(3):357–363.
  • Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int J Mol Sci. 2020;21(10):3570.
  • Landecho MF, Tuero C, Valentí V, Bilbao I, de la Higuera M, Frühbeck G. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk. Nutrients. 2019;11(11):2664.
  • Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27–32.
  • Zhuang L, Li C, Chen Q, Jin Q, Wu L, Lu L, Yan X, Chen K. Fatty acid-binding protein 3 contributes to ischemic heart injury by regulating cardiac myocyte apoptosis and MAPK pathways. Am J Physiol Heart Circ Physiol. 2019;316(5):H971–H984.
  • Matsuda M, Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15(1):1–10.
  • Kryfti M, Dimakou K, Toumbis M, Daniil Z, Hatzoglou C, Gourgoulianis KI. Effects of smoking cessation on serum leptin and adiponectin levels. Tob Induc Dis. 2015;13:30.
  • Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T, Ouchi N, Ohashi K, Kihara S, Funahashi T, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension. 2005;45(6):1094–1100.
  • Mohammadi S, Hasseinzadeh Attar MJ, Karimi M, et al. The effects of green tea extract on serum adiponectin concentration and insulin resistance in patients with Type 2 Diabetes Mellitus. J Adv Med Biomed Res. 2010;18(70):44–57.
  • Anton IC, Botnariu EG, Coculescu EC, Boanca M, Mititelu-Tartau LM. Particular aspects of evolution of SARS-Cov-2 infection in type 2 diabetic patients. Rom J Leg Med. 2021;29(1):53–59.
  • Gîrlescu N, Botnariu EG, Coculescu EC, Hunea I, Diac M, Gheorghe L, Bulgaru Iliescu D. The haze of diabetic state in legal medicine – a review. Rom J Leg Med. 2021;29(2):212–217.
  • Olesen LL, Andersen A. ECG as a first step in the detection of left ventricular systolic dysfunction in the elderly. ESC Heart Fail. 2016;3(1):44–52.
  • Lenarduzzi Júnior RM, de Almeida Neto OP, Pedrosa LA, Silva PC, Coelho VM, Resende ES, Mendes DS. Electrocardiographic and echocardiographic profile of patients with heart failure. Am J Cardiovasc Dis. 2021;11(6):695–703.
  • Jang D-i, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B, Lee S-R, Yang S-H. The role of tumor necrosis factor Alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719.
  • Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab. 2007;9(3):282–289.
  • Jung HN, Jung CH. The role of anti-inflammatory adipokines in cardiometabolic disorders: moving beyond adiponectin. Int J Mol Sci. 2021;22(24):13529.
  • Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011;15(2):221.
  • Song HJ, Oh S, Quan S, Ryu O-H, Jeong J-Y, Hong K-S, Kim D-H. Gender differences in adiponectin levels and body composition in older adults: Hallym aging study. BMC Geriatr. 2014;14:8.